WO2005105074A3 - Composition pour prevenir ou traiter la degenerescence cellulaire en utilisant au moins une molecule capable de mantenir la reversibilite de l’expression des molecules d’adherence et la polymerisation des fibres d’actine de l’endothelium vasculaire - Google Patents

Composition pour prevenir ou traiter la degenerescence cellulaire en utilisant au moins une molecule capable de mantenir la reversibilite de l’expression des molecules d’adherence et la polymerisation des fibres d’actine de l’endothelium vasculaire Download PDF

Info

Publication number
WO2005105074A3
WO2005105074A3 PCT/FR2005/001008 FR2005001008W WO2005105074A3 WO 2005105074 A3 WO2005105074 A3 WO 2005105074A3 FR 2005001008 W FR2005001008 W FR 2005001008W WO 2005105074 A3 WO2005105074 A3 WO 2005105074A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
reversibility
polymerisation
composition
vascular endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/001008
Other languages
English (en)
Other versions
WO2005105074A2 (fr
Inventor
Alessio Patrizia D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP05762397.7A priority Critical patent/EP1748771B1/fr
Priority to ES05762397.7T priority patent/ES2486247T3/es
Publication of WO2005105074A2 publication Critical patent/WO2005105074A2/fr
Publication of WO2005105074A3 publication Critical patent/WO2005105074A3/fr
Priority to US11/584,556 priority patent/US8912230B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention a pour objet l'utilisation d'une molécule choisie dans le groupe comprenant l'acétate de géranyl, le géraniol, l'isomenthone, le limonène, ou le mélange d'au moins deux de celles-ci pour la préparation d'un médicament utile pour prévenir ou traiter la sénescence des cellules endothéliales vasculaires et la dégénérescence des tissus sous-jacents induite par des épisodes inflammatoires répétés. Plus particulièrement, le médicament est utile pour traiter la sénescence des cellules endothéliales vasculaires et la dégénérescence des tissus induite par des épisodes inflammatoires répétés résultant de la présence de cellules cancéreuses.
PCT/FR2005/001008 2004-04-23 2005-04-22 Composition pour prevenir ou traiter la degenerescence cellulaire en utilisant au moins une molecule capable de mantenir la reversibilite de l’expression des molecules d’adherence et la polymerisation des fibres d’actine de l’endothelium vasculaire Ceased WO2005105074A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05762397.7A EP1748771B1 (fr) 2004-04-23 2005-04-22 Composition pour prevenir ou traiter la degenerescence cellulaire en utilisant au moins une molecule capable de mantenir la reversibilite de l'expression des molecules d'adherence et la polymerisation des fibres d'actine de l'endothelium vasculaire
ES05762397.7T ES2486247T3 (es) 2004-04-23 2005-04-22 Composición para prevenir o tratar la degeneración celular utilizando por lo menos una molécula que puede mantener la reversibilidad de la expresión de las moléculas de adherencia y la polimerización de las fibras de actina del endotelio vascular
US11/584,556 US8912230B2 (en) 2004-04-23 2006-10-23 Method for treating cell degeneration using at least one molecule capable of inhibiting adhesion molecule expression and vascular endothelium actin fibre polymerization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0404344A FR2869230B1 (fr) 2004-04-23 2004-04-23 Composition pour prevenir ou traiter la degenerescence cellulaire en utilisant au moins une molecule capable de maintenir la reversibilite de l'expression des molecules d'adherence et la polymerisation des fibres d'actine
FR0404344 2004-04-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/584,556 Continuation US8912230B2 (en) 2004-04-23 2006-10-23 Method for treating cell degeneration using at least one molecule capable of inhibiting adhesion molecule expression and vascular endothelium actin fibre polymerization

Publications (2)

Publication Number Publication Date
WO2005105074A2 WO2005105074A2 (fr) 2005-11-10
WO2005105074A3 true WO2005105074A3 (fr) 2006-01-12

Family

ID=34953928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001008 Ceased WO2005105074A2 (fr) 2004-04-23 2005-04-22 Composition pour prevenir ou traiter la degenerescence cellulaire en utilisant au moins une molecule capable de mantenir la reversibilite de l’expression des molecules d’adherence et la polymerisation des fibres d’actine de l’endothelium vasculaire

Country Status (5)

Country Link
US (1) US8912230B2 (fr)
EP (1) EP1748771B1 (fr)
ES (1) ES2486247T3 (fr)
FR (1) FR2869230B1 (fr)
WO (1) WO2005105074A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312780T3 (es) 2002-05-13 2009-03-01 Arexis Ab Afecciones autoinmunes y deficiencias de oxidasa nadph.
NZ570803A (en) * 2006-03-15 2011-06-30 Biovitrum Ab Publ Autoimmune conditions and NADPH oxidase defects
EP1990047A1 (fr) * 2007-05-11 2008-11-12 Aisa Therapeutics Utilisation de monoterpène dans le traitement ou la prévention du stress
EP2042167A1 (fr) * 2007-09-26 2009-04-01 Aisa Therapeutics Utilisation d'un monoterpène pour induire la réparation tissulaire
KR100919897B1 (ko) * 2007-11-05 2009-09-30 바이오스펙트럼 주식회사 이소멘톤을 유효성분으로 포함하는 피부 상태 개선용조성물
US20150320700A1 (en) * 2012-05-07 2015-11-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Reserc Organizatio Geranium oil and constituents thereof for treatment of neurodegenerative diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671721A1 (fr) * 1991-01-17 1992-07-24 Morier Jean Pierre Produit pour la repigmentation naturelle des poils et des cheveux et l'amelioration de la calvitie.
US5599546A (en) * 1992-06-16 1997-02-04 Klein; Marvin E. Medicinal facial mask
JPH1135455A (ja) * 1997-07-18 1999-02-09 Noevir Co Ltd コラーゲン産生促進剤、及びこれを含有する皮膚の老化防止用又は創傷治癒促進用皮膚外用剤
DE19915102A1 (de) * 1999-04-01 2000-10-05 Pohl Boskamp Gmbh Chem Pharma Verwendung von Limonen zur Behandlung oxidativer Zellschädigungen
WO2001078706A2 (fr) * 2000-04-13 2001-10-25 Cellegy Pharmaceuticals, Inc. Traitement de maladies cutaneo-muqueuses hyperprolifertaives et inflammatoires au moyen d'inhibiteurs de synthese du mevalonate
WO2002013840A1 (fr) * 2000-08-18 2002-02-21 University Of Bern Huiles essentielles et especes chimiquement associees utilisees dans le traitement des maladies associees a l'augmentation de la resorption osseuse
JP2004002237A (ja) * 2002-05-31 2004-01-08 Noriko Yagi 老化防止ハーブ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3126161B2 (ja) * 1991-05-10 2001-01-22 積水化学工業株式会社 炎症性皮膚疾患治療用の外用剤
US6177472B1 (en) * 1995-08-08 2001-01-23 University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease proteins and uses thereof
DE19644422C2 (de) * 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1045822B1 (fr) * 1998-01-09 2003-05-07 Eurovita A/S Certains diterpenes et extraits ou concentres de curcuma amada contenant ceux-ci, utiles comme medicaments
KR100339216B1 (ko) 1999-12-31 2002-05-31 이계안 자동차의 전방필러부 보강구조
KR100395214B1 (ko) * 2000-04-21 2003-08-25 이인수 미나리 추출물을 함유하는 폐암예방 및 전이억제용식이조성물
KR100372562B1 (ko) * 2001-08-17 2003-02-15 한국과학기술연구원 류코트리엔 생성 저해활성을 가지는 정유 성분
US7041706B2 (en) * 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
EP1587482A4 (fr) * 2003-01-31 2010-08-25 Technion Res & Dev Foundation Compositions anti-inflammatoires et leurs utilisations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671721A1 (fr) * 1991-01-17 1992-07-24 Morier Jean Pierre Produit pour la repigmentation naturelle des poils et des cheveux et l'amelioration de la calvitie.
US5599546A (en) * 1992-06-16 1997-02-04 Klein; Marvin E. Medicinal facial mask
JPH1135455A (ja) * 1997-07-18 1999-02-09 Noevir Co Ltd コラーゲン産生促進剤、及びこれを含有する皮膚の老化防止用又は創傷治癒促進用皮膚外用剤
DE19915102A1 (de) * 1999-04-01 2000-10-05 Pohl Boskamp Gmbh Chem Pharma Verwendung von Limonen zur Behandlung oxidativer Zellschädigungen
WO2001078706A2 (fr) * 2000-04-13 2001-10-25 Cellegy Pharmaceuticals, Inc. Traitement de maladies cutaneo-muqueuses hyperprolifertaives et inflammatoires au moyen d'inhibiteurs de synthese du mevalonate
WO2002013840A1 (fr) * 2000-08-18 2002-02-21 University Of Bern Huiles essentielles et especes chimiquement associees utilisees dans le traitement des maladies associees a l'augmentation de la resorption osseuse
JP2004002237A (ja) * 2002-05-31 2004-01-08 Noriko Yagi 老化防止ハーブ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200416, Derwent World Patents Index; Class B04, AN 2004-160857, XP002331736 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 05 31 May 1999 (1999-05-31) *
STOHS S J: "THE ROLE OF FREE RADICALS IN TOXICITY AND DISEASE", JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY, FREUND PUBLISHING HOUSE LTD., LONDON, GB, vol. 6, no. 3/4, 1995, pages 205 - 228, XP002040436, ISSN: 0792-6855 *

Also Published As

Publication number Publication date
EP1748771B1 (fr) 2014-04-30
ES2486247T3 (es) 2014-08-18
US8912230B2 (en) 2014-12-16
FR2869230B1 (fr) 2006-07-28
US20090012162A1 (en) 2009-01-08
WO2005105074A2 (fr) 2005-11-10
FR2869230A1 (fr) 2005-10-28
EP1748771A2 (fr) 2007-02-07

Similar Documents

Publication Publication Date Title
WO2009003110A3 (fr) Polymersomes inhibiteurs de metap-2 destinés à l'administration thérapeutique
EP3838935A3 (fr) Compositions polymérisables contenant des monomères (méth)acrylate ayant des liaisons de sulfure
WO2009048145A1 (fr) Composition de résine hydro-absorbante et son procédé de fabrication
WO2005118008A3 (fr) Compositions et articles contenant une matrice polymere reticulee et un liquide actif immobilise et procedes de fabrication et d'utilisation de ceux-ci
WO2007094922A3 (fr) Dérivés d'esters de l'acide lévulinique utiles comme plastifiants réactifs et solvants coalescents
WO2008100867A3 (fr) Nouveaux inhibiteurs de réplication du virus de l'hépatite c
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2004062613A3 (fr) Inhibiteurs d'integrase hiv
WO2000059899A8 (fr) Nouveaux derives de l'acide lipoïque et les compositions pharmaceutiques les contenant
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
WO2004013093A3 (fr) Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci
WO2009066511A1 (fr) Composition de polymère et son utilisation
WO2011073234A3 (fr) Composition d'hormone de croissance
NO20081593L (no) Depotsammensetning
WO2006004741A3 (fr) 3-aminocyclopentanecarboxamides utilises en tant que modulateurs des recepteurs des chimiokines
WO2010059001A3 (fr) Composition de micelles polymères pour le traitement de cellules cancéreuses résistantes
Lasco et al. Carbon budgets of forest ecosystems in the Philippines
WO2006004684A3 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de la chimiokine
WO2010013815A1 (fr) Composition destinée à inhiber l'expression d'un gène cible
WO2007126364A8 (fr) Nouvelle approche du traitement de l'hypertension intraoculaire
WO2012138558A3 (fr) Compositions asphaltiques, matériaux asphaltiques chargés et procédés pour la fabrication de compositions asphaltiques
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
WO2008047061A3 (fr) Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante
WO2009053482A3 (fr) Réactifs de méthylène activés et compositions durcissables préparées à partir de ceux-ci
WO2007128478A3 (fr) Composition pharmaceutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005762397

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005762397

Country of ref document: EP